Silence Therapeutics plc Banner Image

Silence Therapeutics plc

  • Ticker SLN
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Silence Therapeutics plc Logo Image
  • 51-200 Employees
  • Based in London, England
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ Platform can be used to create siRNAs that precisely target and silenceMore disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others.
4.8 / 5.0 (120)

Silence Therapeutics plc reports have an aggregate usefulness score of 4.8 based on 120 reviews.

Silence Therapeutics plc

Most Recent Annual Report

Silence Therapeutics plc
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Silence Therapeutics plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!